Ideagen plc provided earnings guidance for the six months ended 31 October 2016. The company expects revenue and adjusted EBITDA to show a significant increase over the same period last year through a combination of organic growth and the acquisition of Covalent. The Group expects to report organic revenue growth of approximately 16% together with a small contribution from Covalent which was acquired in August 2016. The integration of Covalent is complete and the Company expects an increased level of contribution in the second half. Consequently, the Company continues to trade in line with market expectations for the full year to 30 April 2017.